Traws Pharma, Inc. Net Fee Amt
Traws Pharma, Inc. (TRAW) had Net Fee Amt of $0 as of 2026-06-30, per its S-3 filed 2026-07-01.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-01
- 2026-06-30: Net Fee Amt $0.00.
- 2026-05-04: Net Fee Amt $7.31K.
| Period end | Net Fee Amt |
|---|---|
| 2026-06-30 | $0.00 S-3 · filed 2026-07-01 |
| 2026-05-04 | $7.31K S-3 · filed 2026-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |